Management of liver diseases: Current perspectives

Table 1 Interrim results of selective drug trials for non-alcoholic fatty liver disease and liver fibrosis

Agent	Mechanism	Phase	ClinicalTrials.gov number	Results
Simtuzumab	Lysyl oxidase-like 2 monoclonal antibody	IIb	NCT01672879	Ineffective in decreasing hepatic venous pressure gradient
Selonsertib	Selective inhibitor of apoptosis signal-regulating kinase 1	III	NCT03053063	Ineffective in improving fibrosis without worsening NASH
Emricasan	Pan-caspase inhibitor	II	NCT03205345	No reduction in composite outcome of mortality and decompensation
Pegbelfermin	PEGylated fibroblast growth factor 21 analogue	IIa	NCT03486912	Ineffective in improving fibrosis without worsening NASH
Lanifibranor	Pan peroxisome proliferator-activated receptor agonists	III	NCT04849728	Decrease of ≥ 2 points in the Steatosis Activity Fibrosis score without worsening of fibrosis in phase 2b trial
Resmetirom	Thyroid hormone receptor agonist	III	NCT03900429	Significant reductions in liver fat content and serum atherogenic lipids in phase 2 trial
Aramchol	Hepatic stearoyl-CoA desaturase1 inhibitor	IIb	NCT02279524	Insignificant decrease in liver triglycerides but significant improvement in liver inflammation and improvement of fibrosis ≥ 1 stage and serum ALT level
Leronlimab	Chemokine receptor 5 monoclonal antibody	II	NCT04521114	Significant drops in liver fat, inflammation and fibrosis values as also in liver enzymes and multiple inflammation markers at week 14 compared to placebo

NASH: Non-alcoholic steatohepatitis; ALT: Alanine transaminase.